查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002644

表观遗传学市场：按产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Epigenetics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，表观遗传学市场价值将达到 19.4 亿美元，到 2026 年将成长到 22.5 亿美元，到 2032 年将达到 59.6 亿美元，复合年增长率为 17.33%。

主要市场统计数据
基准年 2025 19.4亿美元
预计年份：2026年 22.5亿美元
预测年份 2032 59.6亿美元
复合年增长率 (%) 17.33%

表观遗传学研究的战略意义以及推动生命科学领域新的转化和商业性机会的技术进步框架。

表观遗传学正在重塑生命科学界对基因表现调控、疾病发病机制以及在各种应用领域中治疗潜力的理解。检测灵敏度、单细胞层次分析和计算分析的最新进展，使得表观遗传学测量对转化研究人员和商业开发人员更实用。本导言概述了构成此概要的基础，包括其根本驱动因素、技术转折点和相关人员的需求。

本研究评估了技术融合、多体学整合和不断发展的经营模式，这些因素共同重新定义了表观遗传学研究的转化轨迹。

表观遗传学正步入变革阶段，不再局限于渐进式改进，而是在研究流程、临床转化策略和商业性价值链中展现出结构性变革。技术整合是这一趋势的核心。高通量定序、先进质谱和多重检测技术如今正与机器学习主导的分析方法相结合，从复杂的表观基因资料集中提取具有临床意义的讯号。这种融合拓展了研究人员可以提出的问题类型，从绘製细胞状态图谱到分析功能失调。

本分析检视了不断变化的关税制度对供应链韧性、供应商选择和融资筹资策略的营运和采购影响。

政策和贸易措施会对支撑表观遗传学研究和商业化的供应链、设备取得和成本结构产生重大影响。近期关税调整对进口实验室设备、专用试剂以及使用特定软体的服务造成了不利影响。关税制度和分类的变化会影响研究机构和产业团队的采购时间、资本规划和供应商选择。当单一供应商在关键类别中占据主导地位时，这种影响最为严重。

我们建构了一个多层次的细分框架，将产品类型、核心技术、特定领域的应用和不同的最终用户连结起来，从而支援有针对性的策略决策。

明确划分市场区隔是把表观遗传学创新转化为可行的产品和服务策略的关键要素。按产品类型划分，市场可细分为耗材和试剂、仪器以及软体和服务。耗材和试剂可细分为酵素和修饰试剂以及试剂盒和检测方法；仪器可细分为质谱仪、微阵列扫描仪、PCR仪和定序系统；软体和服务则分为合约服务和软体工具。这种产品类型分类突显了经常性收入来源与高价值资本投资之间的交集，而这些都需要长期的检验和服务生态系统。

比较全球主要地区的采用趋势、法规预期和能力建设，以完善商业化和伙伴关係策略。

区域趋势在塑造表观遗传学相关工具和应用的全球发展、传播和商业化过程中发挥着至关重要的作用。美洲地区拥有许多创新中心、活跃的私人资本活动以及紧密交织的製药和生物技术公司网络，正在加速转化研究计划的进展。该地区的研究机构和产业合作伙伴往往主导早期检验研究，并塑造先进设备和合约服务的初始市场。

我们评估平台整合、监管合规和附加价值服务模式所带来的竞争差异化，这些差异化有助于建立可持续的客户关係。

表观遗传学领域的竞争动态取决于深厚的科学专业知识、平台稳定性以及提供端到端解决方案的能力，从而降低应用门槛。领先的仪器供应商透过精准的工程设计、可扩展的扩充性以及缩短实用化时间的整合服务模式来脱颖而出。销售与仪器捆绑销售的检验试剂和检测试剂盒的公司通常拥有更长的客户生命週期，从而简化终端用户的工作流程并缩短检验週期。

领导者面临的实际策略挑战是加快部署速度、减少营运摩擦，并使产品和伙伴关係关係策略与临床和商业性要求保持一致。

产业领导者应优先采取一系列切实可行的步骤，以加速表观遗传学的实用化，并在不断发展的领域中保持竞争优势。首先，应投资于模组化产品架构和检验的试剂组，在减少研究和临床团队整合摩擦的同时，实现持续的收入成长。这种方法可以缩短引进週期，并支援在不同的实验室环境中实现可重复性。

为了支持实际结论，本文檔描述了一种混合研究途径，该方法结合了与主要相关人员的访谈、技术检验审查和严格的证据整合。

支持这些研究结果的调查方法结合了对一级资讯来源的访谈、技术检验审查，以及对同侪审查文献和公开监管文件的系统整合。关键工作包括与仪器製造商、试剂供应商、学术研究人员、临床实验室管理人员和合约研究机构进行对话，以明确实际操作、应用障碍和技术成熟路径。

策略结论总结，将技术进步、营运准备和伙伴关係模式连结起来，以展示将表观遗传学科学转化为可操作解决方案的可行路径。

总之，表观遗传学是一个快速发展的领域，技术创新、转换应用和商业性机会在此交会融合。检测技术、分析方法和表观基因编辑技术的进步，拓展了研究人员能够解答的问题范围和细节程度，从而为诊断和治疗方法的开发开闢了新的途径。营运和政策因素，包括贸易趋势和供应链结构，对企业如何规划采购和扩展自身能力有显着的影响。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：表观遗传学市场：依产品类型划分

  • 耗材和试剂
    • 酵素和修饰试剂
    • 试剂盒检测
  • 装置
    • 质谱仪
    • 微阵列扫描仪
    • PCR装置
    • 定序系统
  • 软体服务
    • 合约服务
    • 软体工具

第九章：表观遗传学市场：依技术划分

  • 染色质可及性分析
  • DNA甲基化
  • 表观基因编辑
  • 组蛋白修饰
  • 非编码RNA（ncRNA）

第十章：表观遗传学市场：依应用领域划分

  • 农业生物技术
  • 自体免疫疾病
  • 心血管疾病
  • 药物发现
    • 先导化合物的鑑定
    • 毒性测试
  • 感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学调查
    • 生物标记发现
    • 诊断
    • 治疗调查

第十一章：表观遗传学市场：依最终用户划分

  • 学术和研究机构
  • 合约研究机构
  • 诊断检测实验室
  • 製药和生物技术公司

第十二章：表观遗传学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：表观遗传学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：表观遗传学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国表观遗传学市场

第十六章：中国表观遗传学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10X Genomics, Inc.
  • Abcam PLC
  • Active Motif, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • CellCentric Ltd.
  • Danaher Corporation
  • Diagenode sa
  • Domainex Ltd.
  • Element Biosciences, Inc.
  • EpiGentek Group Inc.
  • Exact Sciences
  • F. Hoffmann-La Roche AG
  • GeneTex, Inc.
  • Illumina, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Merck KGaA
  • MorphoSys
  • New England Biolabs, Inc.
  • Pacific Biosciences
  • PerkinElmer, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corp.
Product Code: MRR-0D217D5ADE3D

The Epigenetics Market was valued at USD 1.94 billion in 2025 and is projected to grow to USD 2.25 billion in 2026, with a CAGR of 17.33%, reaching USD 5.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.94 billion
Estimated Year [2026] USD 2.25 billion
Forecast Year [2032] USD 5.96 billion
CAGR (%) 17.33%

Framing the strategic relevance of epigenetics research and technological advances that are driving new translational and commercial opportunities in life sciences

Epigenetics is reshaping how the life sciences community understands gene regulation, disease etiology, and therapeutic opportunity across a diverse range of applications. Recent advances in assay sensitivity, single-cell resolution, and computational analytics have converged to make epigenetic measurements more actionable for translational researchers and commercial developers alike. This introduction summarizes the underlying drivers, technological inflection points, and stakeholder needs that frame the rest of this executive-level synthesis.

Emerging scientific consensus emphasizes that epigenetic modifications are both markers of cellular state and modulators of function, which creates dual-value propositions for diagnostics and therapeutics. Concurrently, instrument innovation and better reagent chemistry are reducing barriers to routine implementation in both research and clinical contexts. As a result, cross-disciplinary teams from academic labs, contract organizations, diagnostic services, and industry research groups are integrating epigenetic endpoints into study designs to augment molecular readouts with regulatory-layer insights.

Taken together, these forces reiterate an important strategic reality: decision-makers must evaluate not only scientific validity but operational feasibility and partnership models that accelerate translation. This introduction therefore sets expectations for the subsequent sections, which cover landscape shifts, policy impacts, segmentation intelligence, regional dynamics, competitive positioning, actionable recommendations, and the research methodology that supports the conclusions offered here.

Assessing technological convergence, multi-omic integration, and commercial model evolution that are collectively redefining translational trajectories in epigenetics research

Epigenetics has entered a phase characterized by transformative shifts that transcend incremental improvements and point to structural change in research workflows, clinical translational strategies, and commercial value chains. Technological integration is a central theme: high-throughput sequencing, advanced mass spectrometry, and multiplexed assays are now interfacing with machine learning-driven analytics to extract clinically relevant signals from complex epigenomic datasets. This convergence is expanding the types of questions researchers can ask, from cell-state mapping to functional perturbation analysis.

Another major shift is the normalization of multi-omic study designs that position epigenetic data alongside genomic, transcriptomic, proteomic, and metabolomic layers. This systemic view improves biomarker robustness and supports mechanistic insights for therapeutic intervention. In parallel, the maturation of epigenome editing tools is opening therapeutic pathways that were previously conceptual, enabling targeted modulation of gene regulation with increasing specificity and improved delivery strategies.

Finally, commercial and operational shifts are apparent. Contract research providers and diagnostic laboratories are embedding epigenetic assays into service portfolios, and cross-sector partnerships are accelerating commercialization timelines for both tools and therapeutics. These shifts require adaptive business models that combine scientific excellence with scalable manufacturing, regulatory strategy, and validation pathways designed to meet clinical-grade evidence standards. Collectively, these transformational forces are redefining the boundaries of what is scientifically feasible and commercially viable within epigenetics.

Analyzing the operational and procurement implications of evolving tariff regimes that are reshaping supply chain resilience, vendor selection, and capital acquisition strategies

Policy and trade measures can materially influence supply chains, instrument access, and cost structures that underlie epigenetics research and commercialization. Recent tariff adjustments have introduced headwinds that affect imported laboratory instruments, specialized reagents, and certain software-enabled services. Changes to duty regimes and customs classifications influence procurement timing, capital planning, and vendor selection for research institutions and industry teams, and they are most acute where single-source suppliers dominate critical categories.

Operational teams have responded by diversifying suppliers, pre-negotiating long-lead procurement contracts, and pursuing local sourcing where feasible for reagents and consumables. In parallel, instrument vendors are increasingly offering financing, on-site installation, and bundled service contracts to mitigate acquisition friction introduced by trade measures. These shifts alter total acquisition cost profiles and may favor vendors with localized manufacturing or established distribution networks.

Importantly, businesses that invest in supply chain resilience and flexible procurement strategies gain competitive advantage. Risk mitigation practices, such as maintaining multi-vendor specifications, second-source reagent validation, and regional logistics planning, improve continuity of research operations. From a strategic perspective, understanding the cumulative operational implications of tariff changes enables stakeholders to prioritize investments that sustain productivity while preserving options for future scaling and regulatory compliance.

Developing a layered segmentation framework that links product categories, core technologies, domain-specific applications, and varied end users to inform targeted strategic decisions

Segmentation clarity is a foundational element for translating epigenetics innovation into actionable product and service strategies. Across product types, the landscape is categorized into consumables and reagents, instruments, and software and services, with consumables and reagents further differentiating into enzymes and modification reagents and kits and assays, instruments subdivided into mass spectrometers, microarray scanners, PCR instruments, and sequencing systems, and software and services separating into contract services and software tools. This product-type breakdown highlights where recurring revenue streams intersect with high-capital purchases that require extended validation and service ecosystems.

From a technology perspective, the field encompasses chromatin accessibility assays, DNA methylation, epigenome editing, histone modification, and non-coding RNA modalities, each with distinct experimental requirements, analytical pipelines, and translational use cases. These technology distinctions inform R&D prioritization because assay complexity, throughput, and interpretive frameworks differ significantly across the set.

Application segmentation reflects a broad set of research and development imperatives including agricultural biotechnology, autoimmune diseases, cardiovascular diseases, drug discovery, infectious diseases, metabolic disorders, neurological disorders, and oncology research, where drug discovery itself bifurcates into lead identification and toxicology studies and oncology research further divides into biomarker discovery, diagnostics, and therapeutic research. This application orientation clarifies end-user needs and evidentiary thresholds for analytic validity, clinical utility, and regulatory acceptance.

End-user segmentation includes academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotechnology companies, and it underscores variation in budget cycles, procurement drivers, and adoption velocity. Taken together, this layered segmentation framework enables more precise competitive targeting, product roadmapping, and partnership strategies by aligning technical capabilities with end-user workflows and unmet needs.

Comparing regional adoption dynamics, regulatory expectations, and capacity building across major world regions to refine commercialization and partnership strategies

Regional dynamics play a decisive role in shaping how epigenetics tools and applications evolve, diffuse, and commercialize globally. The Americas exhibit concentrated centers of innovation, strong private capital activity, and dense networks of pharmaceutical and biotech companies that accelerate translational projects. Research institutions and industry partners in the region often drive early validation studies and form the initial markets for advanced instruments and contract services.

Europe, Middle East & Africa combine regulatory complexity with heterogeneous research infrastructure; while some countries host world-class translational capabilities, others are in earlier stages of adoption. This region places particular emphasis on harmonized clinical evidence and regulatory alignment, which influences study design and data interoperability. Partnerships that bridge national research centers and public health systems can facilitate broader access to epigenetic diagnostics and therapeutic trials.

Asia-Pacific is characterized by rapid capacity building, increasing investment in domestic instrument and reagent production, and growing emphasis on local clinical validation. Academic and industrial investments in the region are expanding both basic science pipelines and applied therapeutic research. Supply chain considerations and local manufacturing capacity also inform vendor strategies, with an emphasis on scalable distribution and service networks that support regional adoption.

Understanding these regional nuances allows stakeholders to align commercialization tactics, clinical collaboration models, and supply chain strategies with the distinctive regulatory environments, funding structures, and adoption pathways that shape demand across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Evaluating competitive differentiation driven by platform integration, regulatory readiness, and value-added service models that underpin durable customer relationships

Competitive dynamics in epigenetics are defined by a combination of deep scientific expertise, platform robustness, and the ability to deliver end-to-end solutions that lower barriers to adoption. Leading instrument vendors differentiate through precision engineering, throughput scalability, and integrated service models that reduce the time from purchase to productive use. Companies that bundle validated reagents and assay kits with instruments often secure longer customer lifecycles because they simplify operational workflows and shorten validation timelines for end users.

Software and analytics providers compete on algorithmic transparency, ease of integration with laboratory information management systems, and the capacity to handle multi-omic datasets at scale. Contract services players that can rapidly operationalize complex epigenetic assays for translational studies, clinical validation, and toxicology testing are in a position to capture demand from sponsors seeking to outsource specialized workflows.

Strategic alliances and licensing arrangements are common, as firms leverage complementary capabilities to accelerate product development and market entry. Firms that invest in regulatory evidence packages, robust clinical validation, and repeatable quality systems gain credibility with institutional customers and clinical partners. Ultimately, competitive advantage accrues to organizations that combine scientific leadership with operational excellence, flexible commercial models, and the capacity to support customers across the research-to-clinic continuum.

Practical strategic imperatives for leaders to accelerate adoption, reduce operational friction, and align product and partnership strategies with clinical and commercial requirements

Industry leaders should prioritize a set of actionable steps that accelerate translation and secure competitive advantage in the evolving epigenetics landscape. First, invest in modular product architectures and validated reagent kits that lower integration friction for research and clinical teams while enabling recurring revenue. This approach shortens onboarding cycles and supports reproducibility across diverse laboratory settings.

Second, build strategic partnerships that combine instrument capabilities with analytics and contract services to deliver turnkey solutions for translational programs. Collaborative models that share development risk and co-develop validation pathways enhance market access and reduce time to clinical utility. Third, strengthen supply chain resilience through diversified sourcing, regional warehousing, and second-source validation for critical reagents to mitigate exposure to trade fluctuations and logistics disruptions.

Fourth, commit to rigorous evidence generation that addresses clinical validity, utility, and analytical performance to meet regulatory and payer expectations. Fifth, tailor go-to-market strategies by region and end user: align pricing, service levels, and training programs with local adoption patterns and regulatory requirements. Finally, invest in talent and cross-disciplinary teams that bridge assay chemistry, instrumentation, and computational biology to sustain innovation and operational delivery over the medium term.

Describing a mixed-methods research approach that integrates primary stakeholder interviews, technology validation reviews, and rigorous evidence synthesis to support practical conclusions

The research methodology underpinning these insights combines primary source interviews, technology validation reviews, and structured synthesis of peer-reviewed literature and public regulatory documentation. Primary engagement included conversations with instrument manufacturers, reagent suppliers, academic investigators, clinical laboratory directors, and contract research providers to surface operational realities, adoption barriers, and technology maturation pathways.

Technology validation reviews evaluated assay performance attributes, workflow complexity, and integration needs across key epigenetics modalities such as chromatin accessibility assays and DNA methylation profiling. Evidence synthesis prioritized peer-reviewed studies, preprints with replication cohorts, and regulatory guidance documents where applicable, while explicitly weighting translational relevance and reproducibility.

Analytical triangulation reconciled qualitative inputs with documented product capabilities and published validation studies to produce balanced judgments about strategic implications without relying on proprietary market estimates. Where trade and policy impacts were examined, the methodology incorporated customs documentation, tariff schedules, and vendor supply chain disclosures to assess operational implications and mitigation strategies. This mixed-methods approach ensures that conclusions are grounded in verifiable technical evidence and stakeholder experience.

Summarizing strategic conclusions that connect technological progress, operational readiness, and partnership models to actionable paths for translating epigenetic science into practical solutions

In closing, epigenetics represents a rapidly maturing domain where technical innovation, translational ambition, and commercial opportunity intersect. Advances in assay technology, analytics, and epigenome editing are expanding both the scope and the granularity of questions that researchers can answer, which in turn creates new pathways for diagnostics and therapeutic development. Operational and policy factors, including trade dynamics and supply chain configuration, materially affect how organizations plan procurement and scale capabilities.

Decision-makers should therefore align scientific strategy with operational readiness, regulatory planning, and partnership models that accelerate product validation and clinical integration. By combining modular product designs, evidence-focused development, supply chain resilience, and tailored regional strategies, organizations can transform epigenetic potential into measurable impact for patients and customers. The conclusions presented here serve as a roadmap for leaders intent on translating complex science into robust, reproducible, and commercially viable solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Epigenetics Market, by Product Type

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Modification Reagents
    • 8.1.2. Kits & Assays
  • 8.2. Instruments
    • 8.2.1. Mass Spectrometers
    • 8.2.2. Microarray Scanners
    • 8.2.3. PCR Instruments
    • 8.2.4. Sequencing Systems
  • 8.3. Software & Services
    • 8.3.1. Contract Services
    • 8.3.2. Software Tools

9. Epigenetics Market, by Technology

  • 9.1. Chromatin Accessibility Assays
  • 9.2. DNA Methylation
  • 9.3. Epigenome Editing
  • 9.4. Histone Modification
  • 9.5. Non-coding RNA (ncRNA)

10. Epigenetics Market, by Application

  • 10.1. Agricultural Biotechnology
  • 10.2. Autoimmune Diseases
  • 10.3. Cardiovascular Diseases
  • 10.4. Drug Discovery
    • 10.4.1. Lead Identification
    • 10.4.2. Toxicology Studies
  • 10.5. Infectious Diseases
  • 10.6. Metabolic Disorders
  • 10.7. Neurological Disorders
  • 10.8. Oncology Research
    • 10.8.1. Biomarker Discovery
    • 10.8.2. Diagnostics
    • 10.8.3. Therapeutic Research

11. Epigenetics Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Epigenetics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Epigenetics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Epigenetics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Epigenetics Market

16. China Epigenetics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10X Genomics, Inc.
  • 17.6. Abcam PLC
  • 17.7. Active Motif, Inc.
  • 17.8. Agilent Technologies, Inc.
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. CellCentric Ltd.
  • 17.11. Danaher Corporation
  • 17.12. Diagenode s.a.
  • 17.13. Domainex Ltd.
  • 17.14. Element Biosciences, Inc.
  • 17.15. EpiGentek Group Inc.
  • 17.16. Exact Sciences
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. GeneTex, Inc.
  • 17.19. Illumina, Inc.
  • 17.20. Ipsen Biopharmaceuticals, Inc.
  • 17.21. Merck KGaA
  • 17.22. MorphoSys
  • 17.23. New England Biolabs, Inc.
  • 17.24. Pacific Biosciences
  • 17.25. PerkinElmer, Inc.
  • 17.26. Promega Corporation
  • 17.27. QIAGEN N.V.
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. Zymo Research Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EPIGENETICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EPIGENETICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EPIGENETICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EPIGENETICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EPIGENETICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EPIGENETICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EPIGENETICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EPIGENETICS MARKET SIZE, BY ENZYMES & MODIFICATION REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EPIGENETICS MARKET SIZE, BY ENZYMES & MODIFICATION REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EPIGENETICS MARKET SIZE, BY ENZYMES & MODIFICATION REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EPIGENETICS MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EPIGENETICS MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EPIGENETICS MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EPIGENETICS MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EPIGENETICS MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EPIGENETICS MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EPIGENETICS MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EPIGENETICS MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EPIGENETICS MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EPIGENETICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EPIGENETICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EPIGENETICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EPIGENETICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EPIGENETICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EPIGENETICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EPIGENETICS MARKET SIZE, BY SOFTWARE TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EPIGENETICS MARKET SIZE, BY CHROMATIN ACCESSIBILITY ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EPIGENETICS MARKET SIZE, BY CHROMATIN ACCESSIBILITY ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EPIGENETICS MARKET SIZE, BY CHROMATIN ACCESSIBILITY ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EPIGENETICS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EPIGENETICS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EPIGENETICS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EPIGENETICS MARKET SIZE, BY EPIGENOME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EPIGENETICS MARKET SIZE, BY EPIGENOME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EPIGENETICS MARKET SIZE, BY EPIGENOME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EPIGENETICS MARKET SIZE, BY HISTONE MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EPIGENETICS MARKET SIZE, BY HISTONE MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EPIGENETICS MARKET SIZE, BY HISTONE MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EPIGENETICS MARKET SIZE, BY NON-CODING RNA (NCRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EPIGENETICS MARKET SIZE, BY NON-CODING RNA (NCRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EPIGENETICS MARKET SIZE, BY NON-CODING RNA (NCRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EPIGENETICS MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EPIGENETICS MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EPIGENETICS MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EPIGENETICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EPIGENETICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EPIGENETICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EPIGENETICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EPIGENETICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EPIGENETICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EPIGENETICS MARKET SIZE, BY LEAD IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EPIGENETICS MARKET SIZE, BY LEAD IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EPIGENETICS MARKET SIZE, BY LEAD IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EPIGENETICS MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EPIGENETICS MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EPIGENETICS MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EPIGENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EPIGENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EPIGENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EPIGENETICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EPIGENETICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EPIGENETICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EPIGENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EPIGENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EPIGENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EPIGENETICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EPIGENETICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EPIGENETICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EPIGENETICS MARKET SIZE, BY THERAPEUTIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EPIGENETICS MARKET SIZE, BY THERAPEUTIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EPIGENETICS MARKET SIZE, BY THERAPEUTIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EPIGENETICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EPIGENETICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EPIGENETICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EPIGENETICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EPIGENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EPIGENETICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EPIGENETICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EPIGENETICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EPIGENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS EPIGENETICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL EPIGENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GCC EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 211. GCC EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 241. G7 EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. NATO EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 251. NATO EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA EPIGENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA EPIGENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA EPIGENETICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA EPIGENETICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA EPIGENETICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA EPIGENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA EPIGENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA EPIGENETICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA EPIGENETICS MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA EPIGENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)